Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Nephrology

Decoding Your Kidney Biopsy and the MEST-C Score

At a Glance

The Oxford MEST-C system describes active inflammation and permanent scarring in an IgA nephropathy kidney biopsy. Doctors interpret M, E, S, T, and C findings together with eGFR, proteinuria, and blood pressure to assess kidney risk.

A kidney biopsy is the “gold standard” for diagnosing IgA Nephropathy (IgAN). While blood and urine tests suggest a problem, only a biopsy can confirm that IgA deposits are the dominant force causing inflammation in your kidney’s filters [1].

Once the biopsy is performed, pathologists use a standardized system called the Oxford MEST-C Score to describe what they see. This score helps your doctor understand two things: how much active inflammation is happening right now and how much permanent damage has already occurred [2].

Breaking Down the MEST-C Score

The score is made up of five letters, each representing a specific type of change in the kidney tissue. It is a set of descriptors, not a single severity score, and it does not dictate your treatment alone.

  • M (Mesangial Hypercellularity): This measures an overgrowth of cells in the mesangium, the central support structure of the kidney filter. A score of M1 means there are too many cells [2].
  • E (Endocapillary Hypercellularity): This refers to extra cells inside the tiny blood vessels (capillaries) of the kidney. E1 indicates hypercellularity that may be active [3].
  • S (Segmental Glomerulosclerosis): “Sclerosis” is a medical word for scarring. S1 means that parts of some filters have become scarred. This is a sign of past damage and is a strong marker for the risk of the disease progressing over time [4].
  • T (Tubular Atrophy & Interstitial Fibrosis): This measures scarring in the “tubules” (the tubes that process urine) and the surrounding tissue. It is scored from T0 (0-25%), T1 (26-50%), to T2 (more than 50% scarring) [5]. T scores are often the most reliable predictors of long-term kidney function decline [6].
  • C (Crescents): A crescent is a moon-shaped layer of extra cells that forms when a filter is severely damaged. C0 means no crescents; C1 means crescents in less than 25% of glomeruli; C2 means crescents in 25% or more [7]. Crescents can be cellular or fibrous.

Active Inflammation vs. Permanent Scarring

The MEST-C score helps distinguish between “active” lesions and “chronic” lesions that are permanent.

Score Component Meaning Type of Damage
M and E Cell overgrowth Active
C (Crescents) Cellular extra layer Active
S and T Scarring and atrophy Chronic (Permanent change)

The S and T scores are particularly important for your long-term outlook. Because scarring cannot be undone, high S and T scores tell your doctor that protecting your remaining healthy kidney tissue is the top priority [8][9].

Do Crescents © Mean an Emergency?

Seeing “crescents” on a report can be scary because they represent intense inflammation. However, having a C1 or C2 score does not automatically mean you have the emergency condition called Rapidly Progressive Glomerulonephritis (RPGN) [10].

RPGN is a clinical diagnosis defined by a 50% drop in kidney function in less than three months [11]. If your kidney function (eGFR) is stable, crescents are simply a sign of “active” disease that your doctor will monitor closely, rather than a sign of an immediate crash [12].

The Biopsy is Just One Piece

While the MEST-C score is powerful, it is never used in isolation. International guidelines (KDIGO) emphasize that pathology must be combined with your clinical data [13]:

  1. eGFR: How well your kidneys are currently filtering.
  2. Proteinuria: How much protein you are leaking.
  3. Blood Pressure: How much strain is on your kidneys.

Your doctor uses these numbers together with your biopsy to calculate your risk. A biopsy shows the “weather” inside your kidney on one specific day, but your clinical numbers show the “climate” over time [14][15]. This combined view is what ultimately guides your treatment plan.

Common questions in this guide

What does the MEST-C score mean in IgA nephropathy?
MEST-C is a set of five biopsy descriptors: M and E describe cellular activity, S and T describe scarring, and C describes crescents. It helps clinicians assess active inflammation and chronic damage, but it does not determine treatment by itself.
Is a C1 or C2 crescent finding an emergency?
Not necessarily. C1 or C2 indicates crescents in the biopsy, but this finding alone does not diagnose rapidly progressive glomerulonephritis. That condition is defined by a 50% drop in kidney function in less than three months, so your doctor also considers your eGFR trend and other clinical data.
What do S1 and T scores mean on an IgA nephropathy biopsy?
S1 means segmental glomerulosclerosis, or scarring in parts of some kidney filters. T0, T1, and T2 represent 0–25%, 26–50%, and more than 50% tubular atrophy and interstitial fibrosis; higher T findings indicate more chronic damage and can signal greater risk of long-term kidney function decline.
How are MEST-C results used with blood and urine tests?
Biopsy findings are interpreted along with eGFR, urine protein, and blood pressure. These clinical measures show how the kidneys are functioning over time, while the biopsy shows tissue changes on one day, so the combined information guides risk assessment and care.
Does a kidney biopsy confirm IgA nephropathy?
A kidney biopsy is the gold standard for confirming IgA nephropathy because it can show IgA deposits in the kidney’s filtering units. Blood and urine tests can suggest kidney disease, but they cannot by themselves confirm that IgA deposits are causing the inflammation.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Immunoglobulin A nephropathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What are my specific M, E, S, T, and C scores, and how do they compare to my current eGFR and protein levels?
  2. 2.Does my 'S' or 'T' score suggest that I have significant permanent scarring, and how does that change our goals for my treatment?
  3. 3.My report shows crescents (C score); does the number of crescents suggest I am at risk for rapid kidney decline, or is it considered a focal finding?
  4. 4.How many glomeruli were captured in my biopsy sample? Was the sample large enough to give us a reliable MEST-C score?
  5. 5.Based on my biopsy and my clinical numbers, what does the prediction tool say about my risk over the next five years?

References

References (15)
  1. 1

    IgA Nephropathy in Adults: A Review.

    Stoneman S, Teh JW, O'Shaughnessy MM

    JAMA 2026; (335(9)):799-813 doi:10.1001/jama.2025.25020.

    PMID: 41587026
  2. 2

    The Association of the Oxford Classification Score with Longitudinal Estimated Glomerular Filtration Rate Decline in Patients with Immunoglobulin A Nephropathy: A Mixed-Method Study.

    Xu R, Li Z, Cao T, et al.

    International journal of general medicine 2021; (14()):2655-2663 doi:10.2147/IJGM.S313333.

    PMID: 34177274
  3. 3

    Relationship between renal CD68+ infiltrates and the Oxford Classification of IgA nephropathy.

    Soares MF, Genitsch V, Chakera A, et al.

    Histopathology 2019; (74(4)):629-637 doi:10.1111/his.13768.

    PMID: 30303541
  4. 4

    The correlation analysis between the Oxford classification of Chinese IgA nephropathy children and renal outcome - a retrospective cohort study.

    Wu H, Xia Z, Gao C, et al.

    BMC nephrology 2020; (21(1)):247 doi:10.1186/s12882-020-01913-7.

    PMID: 32611399
  5. 5

    The value of sound touch elastography in the noninvasive staging of fibrosis in IgA nephropathy.

    Chen RR, Lan ZK, Huang WJ, et al.

    BMC medical imaging 2026; (26(1)).

    PMID: 42204462
  6. 6

    Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update.

    Coppo R, D'Arrigo G, Tripepi G, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2020; (35(6)):1002-1009 doi:10.1093/ndt/gfy302.

    PMID: 30418652
  7. 7

    A Multicenter Study of the Predictive Value of Crescents in IgA Nephropathy.

    Haas M, Verhave JC, Liu ZH, et al.

    Journal of the American Society of Nephrology : JASN 2017; (28(2)):691-701 doi:10.1681/ASN.2016040433.

    PMID: 27612994
  8. 8

    Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression.

    Chakera A, MacEwen C, Bellur SS, et al.

    Journal of nephrology 2016; (29(3)):367-375 doi:10.1007/s40620-015-0227-8.

    PMID: 26318019
  9. 9

    Prognostic Utility of the MEST-C Score Combined With Clinical Parameters in Hispanic Patients With IgA Nephropathy.

    Alza-Arcila L, Echeverri-Fernández E, Restrepo-Escobar M, et al.

    International journal of nephrology 2025; (2025()):6974280 doi:10.1155/ijne/6974280.

    PMID: 40224579
  10. 10

    Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.

    Rovin BH, Adler SG, Barratt J, et al.

    Kidney international 2021; (100(4)):753-779 doi:10.1016/j.kint.2021.05.015.

    PMID: 34556300
  11. 11

    Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV).

    Floege J, Barratt J, Cook HT, et al.

    Kidney international 2025; (108(4)):548-554 doi:10.1016/j.kint.2025.04.003.

    PMID: 40975525
  12. 12

    Clinical outcomes of IgA nephropathy patients with different proportions of crescents.

    Zhang W, Zhou Q, Hong L, et al.

    Medicine 2017; (96(11)):e6190 doi:10.1097/MD.0000000000006190.

    PMID: 28296731
  13. 13

    Evaluating a New International Risk-Prediction Tool in IgA Nephropathy.

    Barbour SJ, Coppo R, Zhang H, et al.

    JAMA internal medicine 2019; (179(7)):942-952 doi:10.1001/jamainternmed.2019.0600.

    PMID: 30980653
  14. 14

    The MEST score provides earlier risk prediction in lgA nephropathy.

    Barbour SJ, Espino-Hernandez G, Reich HN, et al.

    Kidney international 2016; (89(1)):167-75.

    PMID: 26759049
  15. 15

    Three-Year Clinical Outcomes of the First South Asian Prospective Longitudinal Observational IgA Nephropathy Cohort.

    Alexander S, Varughese S, Franklin R, et al.

    Kidney international reports 2022; (7(2)):305-318 doi:10.1016/j.ekir.2021.11.012.

    PMID: 35155869

This page explains MEST-C findings in IgA nephropathy for informational purposes only and does not replace medical advice. Ask your nephrologist to interpret your biopsy together with your eGFR, proteinuria, and blood pressure.